B. Riley Financial Issues Pessimistic Forecast for OptimizeRx (NASDAQ:OPRX) Stock Price

OptimizeRx (NASDAQ:OPRX) had its price objective cut by B. Riley Financial from $11.00 to $10.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. B. Riley Financial’s price objective suggests a potential upside of 117.44% from the stock’s current price.

OPRX has been the topic of a number of other reports. Stifel Nicolaus cut their price objective on OptimizeRx from $17.00 to $14.00 and set a “buy” rating on the stock in a research report on Wednesday. UBS Group set a $10.00 price objective on OptimizeRx in a research report on Wednesday. Roth Mkm dropped their price target on OptimizeRx from $32.00 to $18.00 and set a “buy” rating on the stock in a research report on Friday, March 6th. Stephens decreased their target price on OptimizeRx from $10.00 to $7.00 and set an “equal weight” rating on the stock in a research note on Wednesday. Finally, Lake Street Capital set a $11.00 price target on shares of OptimizeRx in a research report on Wednesday. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $13.43.

OptimizeRx Price Performance

Shares of NASDAQ OPRX traded down $1.74 during trading hours on Wednesday, reaching $4.60. 1,661,082 shares of the stock traded hands, compared to its average volume of 451,839. The company has a market capitalization of $86.28 million, a P/E ratio of 17.67 and a beta of 1.19. The company has a quick ratio of 3.04, a current ratio of 3.04 and a debt-to-equity ratio of 0.17. OptimizeRx has a 52-week low of $4.60 and a 52-week high of $22.25. The company’s 50-day simple moving average is $6.59 and its two-hundred day simple moving average is $10.94.

OptimizeRx (NASDAQ:OPRX) last posted its quarterly earnings results on Tuesday, May 12th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.13. OptimizeRx had a return on equity of 10.61% and a net margin of 4.69%.The business had revenue of $19.84 million for the quarter, compared to analyst estimates of $18.35 million. Equities research analysts forecast that OptimizeRx will post 0.5 EPS for the current year.

OptimizeRx declared that its Board of Directors has approved a stock repurchase plan on Thursday, March 5th that permits the company to buyback $10.00 million in outstanding shares. This buyback authorization permits the company to purchase up to 6.8% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s management believes its stock is undervalued.

Hedge Funds Weigh In On OptimizeRx

A number of large investors have recently bought and sold shares of OPRX. Quantbot Technologies LP purchased a new stake in shares of OptimizeRx in the second quarter valued at approximately $44,000. BNP Paribas Financial Markets grew its position in OptimizeRx by 119.2% in the second quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock worth $55,000 after acquiring an additional 2,215 shares during the period. State of Alaska Department of Revenue purchased a new position in OptimizeRx in the fourth quarter worth approximately $62,000. Aaron Wealth Advisors LLC purchased a new position in OptimizeRx in the first quarter worth approximately $66,000. Finally, Hsbc Holdings PLC purchased a new position in OptimizeRx in the first quarter worth approximately $85,000. Institutional investors and hedge funds own 76.47% of the company’s stock.

OptimizeRx Company Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.